Menu

Abbott Laboratories achieves double-digit earnings growth

By Staff Correspondent |
Earnings Update by AlphaStreet

We’re driven by a shared mission: to help you live a healthier, fuller life. The revolutionary health technologies and products we create serve that very human purpose. Managing diabetes. Monitoring hearts. Easing chronic pain. Through our products, our science and our partnerships, we work to bring better health to more people, so that our next breakthrough can lead to theirs.

Current Stock Price:

  • $120.73

Market Capitalization:

  • $209.9 billion
  • Enterprise Value (EV): $215.2 billion

Valuation:

  • Trailing P/E: 15.2
  • Forward P/E: 21.8
  • Indicates ABT’s earnings relative to its price are moderate compared with many large healthcare peers.
  • Growth-Adjusted Valuation
    • PEG Ratio: 2.26 (higher number suggests slower expected growth relative to current valuation).
  • Sales & Cash Flow Multiples
    • P/S (Price/Sales): ~4.8
    • P/B (Price/Book): ~4.1
    • P/FCF (Price/Free Cash Flow): ~30.4
    • EV/EBITDA: ~18.3

Advertisement
Top